(Reuters) – Sage Therapeutics will stop development of its experimental drug to treat cognitive impairment in patients with Huntington’s disease after it failed a mid-stage study, the drug developer said on Wednesday.
The drug, dalzanemdor, did not significantly improve cognitive function in patients compared to placebo after 84 days, failing to meet the main goal of the study.
The drug also failed to achieve “statistical significance” in secondary goals of the study, Sage said.
Huntington’s disease is an inherited disorder that causes nerve cells in parts of the brain to gradually break down and die.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shinjini Ganguli and Sriraj Kalluvila)
